TapewireFind a company

person · Reporting owner

Tansey Casey M

Disclosed activity across 12 companies

Tapewire entity
21218
SEC CIK
0001474322

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CARLSMED, INC.CARL · Entity 555110% ownerJuly 24, 2025September 15, 2026
Heartflow, Inc.HTFL · Entity 3993DirectorJune 16, 2026June 18, 2026
Inspire Medical Systems, Inc.INSP · Entity 1186DirectorJuly 15, 2026July 18, 2026
Intersect ENT, Inc.XENT · Entity 127294DirectorJune 01, 2017June 05, 2017
Mobia Medical, Inc.MOBI · Entity 5669DirectorAugust 18, 2026August 21, 2026
SHOULDER INNOVATIONS, INC.SI · Entity 5607Director · 10% ownerOctober 05, 2026October 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CARLSMED, INC.

Report date July 24, 2025 · Filed September 15, 2026 · Amendment

Jointly reported with Presidio Management Group XII, L.L.C., U.S. Venture Partners XII, L.P.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote200,000 Reported balance After 2025-07-24 transaction · row 1 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 1 · 2025-07-24 · Purchase · Acquired 200,000 · Balance 200,000

F1: Stock held by Casey M. Tansey.

Filing footnotes · ownership attribution and instrument terms

F1: Stock held by Casey M. Tansey.

Heartflow, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $32.05 · Expires 2036-06-16Direct16,075 Reported balance After 2026-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-16 · Grant · Acquired 16,075 · Balance 16,075

F1: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date.

Inspire Medical Systems, Inc.

Report date July 15, 2026 · Filed July 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect26,632 Reported balance After 2026-07-15 transaction · row 1
1 source row

Row 1 · 2026-07-15 · Grant · Acquired 346 · Balance 26,632

F1: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy.

Common StockSEC Table I · non-derivativeIndirectBy Family Trust500 Reported balance Holding disclosure · report date 2026-07-15 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 500

F2: Securities held by The Kimberly Tansey Irrevocable Trust.

Common StockSEC Table I · non-derivativeIndirectBy Family Trust500 Reported balance Holding disclosure · report date 2026-07-15 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 500

F3: Securities held by The Kylie Tansey Irrevocable Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy.

F2: Securities held by The Kimberly Tansey Irrevocable Trust.

F3: Securities held by The Kylie Tansey Irrevocable Trust.

Intersect ENT, Inc.

Report date June 01, 2017 · Filed June 05, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,546 Reported balance After 2017-06-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2017-06-01 · Grant · Acquired 2,546 · Balance 2,546

F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 1, 2018.

Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.05 · Expires 2027-05-31Direct6,035 Reported balance After 2017-06-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2017-06-01 · Grant · Acquired 6,035 · Balance 6,035

F2: The shares subject to the option vest in 12 equal monthly installments commencing on June 1, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 1, 2018.

F2: The shares subject to the option vest in 12 equal monthly installments commencing on June 1, 2017.

Mobia Medical, Inc.

Report date August 18, 2026 · Filed August 21, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect318,332 Reported balance After 2026-08-18 transaction · row 1
1 source row

Row 1 · 2026-08-18 · Purchase · Acquired 16,441 · Balance 318,332

F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.90 to $12.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.90 to $12.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SHOULDER INNOVATIONS, INC.

Report date October 05, 2026 · Filed October 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect53,445 Reported balance After 2026-10-05 transaction · row 1
1 source row

Row 1 · 2026-10-05 · Grant · Acquired 733 · Balance 53,445

F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors.

Common StockSEC Table I · non-derivativeIndirectHeld by U.S. Venture Partners XII, L.P.1,686,403 Reported balance Holding disclosure · report date 2026-10-05 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 1,686,403

F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A.

F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares.

Common StockSEC Table I · non-derivativeIndirectHeld by U.S. Venture Partners XII-A, L.P.85,586 Reported balance Holding disclosure · report date 2026-10-05 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 85,586

F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A.

F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares.

Common StockSEC Table I · non-derivativeIndirectHeld by U.S. Venture Partners Select Fund I, L.P.921,130 Reported balance Holding disclosure · report date 2026-10-05 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 921,130

F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A.

F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors.

F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A.

F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares.

Past disclosures · reporting ended (6)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARS Pharmaceuticals, Inc.

Report date December 08, 2020 · Filed December 09, 2020

Jointly reported with Presidio Management Group XII, L.L.C., U.S. Venture Partners XII, L.P., U.S. Venture Partners XII-A, L.P.

Section 16 reporting ended · disclosed 2020-12-09. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy U.S. Venture Partners XII, L.P.2,069,167 Last balance in matching sequence After 2020-12-08 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2020-12-08 · Conversion · Acquired 1,779,969 · Balance 1,779,969

F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Row 2 · 2020-12-08 · Conversion · Acquired 289,198 · Balance 2,069,167

F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy U.S. Venture Partners XII-A, L.P.105,012 Last balance in matching sequence After 2020-12-08 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 3 · 2020-12-08 · Conversion · Acquired 90,335 · Balance 90,335

F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Row 4 · 2020-12-08 · Conversion · Acquired 14,677 · Balance 105,012

F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by Tansey47,619 Reported balance After 2020-12-08 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2020-12-08 · Purchase · Acquired 47,619 · Balance 47,619

F1: The shares were purchased in the Issuer's initial public offering.

Preferred Series B StockSEC Table II · derivative / convertible securityIndirectBy U.S. Venture Partners XII, L.P.0 Reported balance After 2020-12-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2020-12-08 · Conversion · Disposed 6,609,027 · Balance 0

F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Preferred Series B StockSEC Table II · derivative / convertible securityIndirectBy U.S. Venture Partners XII-A, L.P.0 Reported balance After 2020-12-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2020-12-08 · Conversion · Disposed 335,417 · Balance 0

F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Preferred Series C StockSEC Table II · derivative / convertible securityIndirectBy U.S. Venture Partners XII, L.P.0 Reported balance After 2020-12-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2020-12-08 · Conversion · Disposed 1,073,793 · Balance 0

F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Preferred Series C StockSEC Table II · derivative / convertible securityIndirectBy U.S. Venture Partners XII-A, L.P.0 Reported balance After 2020-12-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2020-12-08 · Conversion · Disposed 54,496 · Balance 0

F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were purchased in the Issuer's initial public offering.

F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Section 16 reporting ended · disclosed 2017-06-08. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeIndirectDirectly owned by USVP IX0 Last balance in matching sequence After 2017-06-02 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2017-06-02 · Conversion · Acquired 8,000,000 · Balance 8,000,000

F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Row 2 · 2017-06-02 · Other · Disposed 8,000,000 · Balance 0

F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

F2: Prorata distribution in kind from the partnership without consideration to its limited partners.

F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Class B Common StockSEC Table II · derivative / convertible securityIndirectDirectly owned by USVP IX3,713,775 Reported balance After 2017-06-02 transaction · row 3 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 3 · 2017-06-02 · Conversion · Disposed 8,000,000 · Balance 3,713,775

F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

F2: Prorata distribution in kind from the partnership without consideration to its limited partners.

F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Section 16 reporting ended · disclosed 2018-11-13. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, $0.001 per shareSEC Table I · non-derivativeIndirectDirectly owned by USVP IX0 Reported balance After 2018-11-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2018-11-08 · Other · Disposed 4,280,779 · Balance 0

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Common Stock, $0.001 per shareSEC Table I · non-derivativeDirect856,155 Reported balance After 2018-11-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2018-11-08 · Other · Acquired 856,155 · Balance 856,155

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

Common Stock, $0.001 per shareSEC Table I · non-derivativeDirect0 Reported balance After 2018-11-08 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2018-11-08 · Other · Disposed 856,155 · Balance 0

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

Common Stock, $0.001 per shareSEC Table I · non-derivativeIndirectDirectly owned by Steven Krausz97,593 Last balance in matching sequence After 2018-11-13 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 4 · 2018-11-08 · Other · Acquired 102,093 · Balance 102,093

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Row 5 · 2018-11-12 · Sale · Disposed 2,100 · Balance 99,993

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Row 6 · 2018-11-13 · Sale · Disposed 2,400 · Balance 97,593

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Common Stock, $0.001 per shareSEC Table I · non-derivativeIndirectDirectly owned by David Liddle69,609 Reported balance After 2018-11-08 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 7 · 2018-11-08 · Other · Acquired 69,609 · Balance 69,609

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Common Stock, $0.001 per shareSEC Table I · non-derivativeIndirectDirectly owned by Paul Matteucci60,408 Reported balance After 2018-11-08 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 8 · 2018-11-08 · Other · Acquired 60,408 · Balance 60,408

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Common Stock, $0.001 per shareSEC Table I · non-derivativeIndirectDirectly owned by Jonathan Root85,851 Reported balance After 2018-11-08 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 9 · 2018-11-08 · Other · Acquired 85,851 · Balance 85,851

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Common Stock, $0.001 per shareSEC Table I · non-derivativeIndirectDirectly owned by Casey Tansey60,336 Reported balance After 2018-11-08 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 10 · 2018-11-08 · Other · Acquired 60,336 · Balance 60,336

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Common Stock, $0.001 per shareSEC Table I · non-derivativeIndirectDirectly owned by Philip Young82,370 Reported balance After 2018-11-08 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 11 · 2018-11-08 · Other · Acquired 82,370 · Balance 82,370

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Inari Medical, Inc.

Report date March 16, 2021 · Filed March 18, 2021

Jointly reported with Presidio Management Group X LLC, US VENTURE PARTNERS X LP, USVP X AFFILIATES LP

Section 16 reporting ended · disclosed 2021-03-18. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectDirectly owned by USVP X2,619,872 Reported balance After 2021-03-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2021-03-16 · Other · Disposed 2,619,872 · Balance 2,619,872

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by AFF X83,813 Reported balance After 2021-03-16 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2021-03-16 · Other · Disposed 83,814 · Balance 83,813

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by PMG X.685,827 Reported balance After 2021-03-16 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2021-03-16 · Other · Acquired 685,827 · Balance 685,827

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F3: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by PMG X.0 Reported balance After 2021-03-16 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2021-03-16 · Other · Disposed 685,827 · Balance 0

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F4: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by Tansey242,988 Reported balance After 2021-03-16 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2021-03-16 · Other · Acquired 77,296 · Balance 242,988

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

F3: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

F4: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Section 16 reporting ended · disclosed 2021-08-19. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectDirectly owned by USVP VII4,368,405 Reported balance After 2021-08-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2021-08-17 · Other · Disposed 1,500,000 · Balance 4,368,405

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII.

F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein

Common StockSEC Table I · non-derivativeIndirectDirectly owned by 2180-VII91,008 Reported balance After 2021-08-17 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2021-08-17 · Other · Disposed 31,250 · Balance 91,008

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII.

F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein

Common StockSEC Table I · non-derivativeDirect312 Reported balance After 2021-08-17 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2021-08-17 · Other · Acquired 312 · Balance 312

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2021-08-18 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2021-08-18 · Sale · Disposed 312 · Balance 0

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by EP7-A45,505 Reported balance After 2021-08-18 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2021-08-18 · Sale · Disposed 15,625 · Balance 45,505

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein

Common StockSEC Table I · non-derivativeIndirectDirectly owned by EP7-B45,505 Reported balance After 2021-08-18 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 6 · 2021-08-18 · Sale · Disposed 15,625 · Balance 45,505

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein

Common StockSEC Table I · non-derivativeIndirectDirectly owned by Casey Tansey5,000 Reported balance Holding disclosure · report date 2021-08-17 · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · Balance 5,000

F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII.

F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

eFFECTOR Therapeutics, Inc.

Report date August 01, 2022 · Filed August 03, 2022

Jointly reported with Presidio Management Group X LLC, US VENTURE PARTNERS X LP, USVP X AFFILIATES LP, ROOT JONATHAN D

Section 16 reporting ended · disclosed 2022-08-03. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectDirectly owned by USVP X3,981,940 Last balance in matching sequence After 2022-08-03 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 1 · 2022-08-01 · Sale · Disposed 25,896 · Balance 4,066,868

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Row 3 · 2022-08-02 · Sale · Disposed 27,348 · Balance 4,039,520

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Row 5 · 2022-08-03 · Sale · Disposed 57,580 · Balance 3,981,940

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by AFF X127,569 Last balance in matching sequence After 2022-08-03 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 2 · 2022-08-01 · Sale · Disposed 807 · Balance 130,218

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Row 4 · 2022-08-02 · Sale · Disposed 853 · Balance 129,365

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Row 6 · 2022-08-03 · Sale · Disposed 1,796 · Balance 127,569

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 05, 2021 Filed Feb 6, 2021 00:45 UTC ON24 INC. ONTF · Entity 11630 ConversionClass A-1 Preferred Stock · Derivative 46,701 $0.00 $0.00
Disclosure

SEC source: 0001527715-21-000003 · edgar.xml · derivative · entry 7

PRESIDIO MANAGEMENT GROUP VII L L C · CIK 0001225482 · 10% owner

US VENTURE PARTNERS VII L P · CIK 0001225439 · 10% owner

2180 ASSOCIATES FUND VII L P · CIK 0001225440 · 10% owner

USVP ENTREPRENEUR PARTNERS VII A L P · CIK 0001225442 · 10% owner

USVP ENTREPRENEUR PARTNERS VII B L P · CIK 0001225443 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by 2180 Associates Fund VII, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 46,701 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis upon the closing of the Issuer's intital public offering. The convertible preferred stock had no expiration date.

F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis upon the closing of the Issuer's intital public offering. The convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis upon the closing of the Issuer's intital public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. 2180 Associates Fund VII, L.P., USVP Entrepreneur Partners VII-A, L.P. and USVP Entrepreneur Partners VII-B, L.P. (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
February 05, 2021 Filed Feb 6, 2021 00:45 UTC ON24 INC. ONTF · Entity 11630 ConversionClass A-1 Preferred Stock · Derivative 2,241,670 $0.00 $0.00
Disclosure

SEC source: 0001527715-21-000003 · edgar.xml · derivative · entry 6

PRESIDIO MANAGEMENT GROUP VII L L C · CIK 0001225482 · 10% owner

US VENTURE PARTNERS VII L P · CIK 0001225439 · 10% owner

2180 ASSOCIATES FUND VII L P · CIK 0001225440 · 10% owner

USVP ENTREPRENEUR PARTNERS VII A L P · CIK 0001225442 · 10% owner

USVP ENTREPRENEUR PARTNERS VII B L P · CIK 0001225443 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by U.S. Venture Partners VII, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 2,241,670 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis upon the closing of the Issuer's intital public offering. The convertible preferred stock had no expiration date.

F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis upon the closing of the Issuer's intital public offering. The convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis upon the closing of the Issuer's intital public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. 2180 Associates Fund VII, L.P., USVP Entrepreneur Partners VII-A, L.P. and USVP Entrepreneur Partners VII-B, L.P. (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
February 05, 2021 Filed Feb 6, 2021 00:45 UTC ON24 INC. ONTF · Entity 11630 PurchaseCommon Stock 5,000 $50.00 $250,000.00
Disclosure

SEC source: 0001527715-21-000003 · edgar.xml · nonDerivative · entry 5

PRESIDIO MANAGEMENT GROUP VII L L C · CIK 0001225482 · 10% owner

US VENTURE PARTNERS VII L P · CIK 0001225439 · 10% owner

2180 ASSOCIATES FUND VII L P · CIK 0001225440 · 10% owner

USVP ENTREPRENEUR PARTNERS VII A L P · CIK 0001225442 · 10% owner

USVP ENTREPRENEUR PARTNERS VII B L P · CIK 0001225443 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Casey Tansey

Disclosed balance after: 5,000

F3 · kind: The shares were purchased in the Issuer's initial public offering.

Read SEC document
February 05, 2021 Filed Feb 6, 2021 00:45 UTC ON24 INC. ONTF · Entity 11630 ConversionCommon Stock 76,755 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-21-000003 · edgar.xml · nonDerivative · entry 4

PRESIDIO MANAGEMENT GROUP VII L L C · CIK 0001225482 · 10% owner

US VENTURE PARTNERS VII L P · CIK 0001225439 · 10% owner

2180 ASSOCIATES FUND VII L P · CIK 0001225440 · 10% owner

USVP ENTREPRENEUR PARTNERS VII A L P · CIK 0001225442 · 10% owner

USVP ENTREPRENEUR PARTNERS VII B L P · CIK 0001225443 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by USVP Entrepreneur Partners VII-B, L.P.

Disclosed balance after: 76,755

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis upon the closing of the Issuer's intital public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. 2180 Associates Fund VII, L.P., USVP Entrepreneur Partners VII-A, L.P. and USVP Entrepreneur Partners VII-B, L.P. (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
February 05, 2021 Filed Feb 6, 2021 00:45 UTC ON24 INC. ONTF · Entity 11630 ConversionCommon Stock 76,755 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-21-000003 · edgar.xml · nonDerivative · entry 3

PRESIDIO MANAGEMENT GROUP VII L L C · CIK 0001225482 · 10% owner

US VENTURE PARTNERS VII L P · CIK 0001225439 · 10% owner

2180 ASSOCIATES FUND VII L P · CIK 0001225440 · 10% owner

USVP ENTREPRENEUR PARTNERS VII A L P · CIK 0001225442 · 10% owner

USVP ENTREPRENEUR PARTNERS VII B L P · CIK 0001225443 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by USVP Entrepreneur Partners VII-A, L.P.

Disclosed balance after: 76,755

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis upon the closing of the Issuer's intital public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. 2180 Associates Fund VII, L.P., USVP Entrepreneur Partners VII-A, L.P. and USVP Entrepreneur Partners VII-B, L.P. (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
February 05, 2021 Filed Feb 6, 2021 00:45 UTC ON24 INC. ONTF · Entity 11630 ConversionCommon Stock 153,508 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-21-000003 · edgar.xml · nonDerivative · entry 2

PRESIDIO MANAGEMENT GROUP VII L L C · CIK 0001225482 · 10% owner

US VENTURE PARTNERS VII L P · CIK 0001225439 · 10% owner

2180 ASSOCIATES FUND VII L P · CIK 0001225440 · 10% owner

USVP ENTREPRENEUR PARTNERS VII A L P · CIK 0001225442 · 10% owner

USVP ENTREPRENEUR PARTNERS VII B L P · CIK 0001225443 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by 2180 Associates Fund VII, L.P.

Disclosed balance after: 153,508

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis upon the closing of the Issuer's intital public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. 2180 Associates Fund VII, L.P., USVP Entrepreneur Partners VII-A, L.P. and USVP Entrepreneur Partners VII-B, L.P. (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
February 05, 2021 Filed Feb 6, 2021 00:45 UTC ON24 INC. ONTF · Entity 11630 ConversionCommon Stock 7,368,405 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-21-000003 · edgar.xml · nonDerivative · entry 1

PRESIDIO MANAGEMENT GROUP VII L L C · CIK 0001225482 · 10% owner

US VENTURE PARTNERS VII L P · CIK 0001225439 · 10% owner

2180 ASSOCIATES FUND VII L P · CIK 0001225440 · 10% owner

USVP ENTREPRENEUR PARTNERS VII A L P · CIK 0001225442 · 10% owner

USVP ENTREPRENEUR PARTNERS VII B L P · CIK 0001225443 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by U.S. Venture Partners VII, L.P.

Disclosed balance after: 7,368,405

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis upon the closing of the Issuer's intital public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. 2180 Associates Fund VII, L.P., USVP Entrepreneur Partners VII-A, L.P. and USVP Entrepreneur Partners VII-B, L.P. (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
January 08, 2021 Filed Jan 12, 2021 21:16 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 GrantCommon Stock 70 $194.10 $13,587.00
Disclosure

SEC source: 0001104659-21-003448 · a4.xml · nonDerivative · entry 1

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,005

F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy.

Read SEC document
December 08, 2020 Filed Dec 9, 2020 02:04 UTC ARS Pharmaceuticals, Inc. SBTX · Entity 883 ConversionPreferred Series C Stock · Derivative 54,496 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000027 · edgar.xml · derivative · entry 9

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII-A, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 14,677 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
December 08, 2020 Filed Dec 9, 2020 02:04 UTC ARS Pharmaceuticals, Inc. SBTX · Entity 883 ConversionPreferred Series C Stock · Derivative 1,073,793 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000027 · edgar.xml · derivative · entry 8

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 289,198 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
December 08, 2020 Filed Dec 9, 2020 02:04 UTC ARS Pharmaceuticals, Inc. SBTX · Entity 883 ConversionPreferred Series B Stock · Derivative 335,417 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000027 · edgar.xml · derivative · entry 7

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII-A, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 90,335 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
December 08, 2020 Filed Dec 9, 2020 02:04 UTC ARS Pharmaceuticals, Inc. SBTX · Entity 883 ConversionPreferred Series B Stock · Derivative 6,609,027 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000027 · edgar.xml · derivative · entry 6

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,779,969 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
December 08, 2020 Filed Dec 9, 2020 02:04 UTC ARS Pharmaceuticals, Inc. SBTX · Entity 883 PurchaseCommon Stock 47,619 $21.00 $999,999.00
Disclosure

SEC source: 0001548538-20-000027 · edgar.xml · nonDerivative · entry 5

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Tansey

Disclosed balance after: 47,619

F1 · kind: The shares were purchased in the Issuer's initial public offering.

Read SEC document
December 08, 2020 Filed Dec 9, 2020 02:04 UTC ARS Pharmaceuticals, Inc. SBTX · Entity 883 ConversionCommon Stock 14,677 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-20-000027 · edgar.xml · nonDerivative · entry 4

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII-A, L.P.

Disclosed balance after: 105,012

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
December 08, 2020 Filed Dec 9, 2020 02:04 UTC ARS Pharmaceuticals, Inc. SBTX · Entity 883 ConversionCommon Stock 90,335 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-20-000027 · edgar.xml · nonDerivative · entry 3

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII-A, L.P.

Disclosed balance after: 90,335

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
December 08, 2020 Filed Dec 9, 2020 02:04 UTC ARS Pharmaceuticals, Inc. SBTX · Entity 883 ConversionCommon Stock 289,198 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-20-000027 · edgar.xml · nonDerivative · entry 2

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII, L.P.

Disclosed balance after: 2,069,167

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
December 08, 2020 Filed Dec 9, 2020 02:04 UTC ARS Pharmaceuticals, Inc. SBTX · Entity 883 ConversionCommon Stock 1,779,969 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-20-000027 · edgar.xml · nonDerivative · entry 1

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII, L.P.

Disclosed balance after: 1,779,969

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
November 18, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 SaleCommon Stock 20,000 $66.38 $1,327,600.00
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 7

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Lewis

Disclosed balance after: 40,883

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.52 to $67.32, inclusive for sales on 11/18/2020. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 34,576 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 12

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly held by Krausz childrens trusts

Disclosed balance after: 34,576

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

F7 · ownership.nature: Held by affiliated trusts for the benefit of Krausz children.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 34,576 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 11

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly held by Krausz childrens trusts

Disclosed balance after: 34,576

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

F7 · ownership.nature: Held by affiliated trusts for the benefit of Krausz children.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 11,794 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 10

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly held by family trust controlled by Krausz

Disclosed balance after: 11,794

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 67,730 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 9

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Tansey

Disclosed balance after: 67,730

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 56,173 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 8

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly held by family trust controlled by Matteucci

Disclosed balance after: 56,173

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 60,883 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 6

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Lewis

Disclosed balance after: 60,883

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 37,268 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 5

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Federman

Disclosed balance after: 37,268

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 587,851 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 4

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by PMG X

Disclosed balance after: 0

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F4 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by PMG X, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 587,851 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 3

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by PMG X

Disclosed balance after: 587,851

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F3 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by PMG X, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 71,840 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 2

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by AFF X

Disclosed balance after: 167,627

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F2 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP") and USVP X Affiliates Fund , L.P. ("AFF X" and, together with USVP X, the "USVP Funds", and may be deemed to have sole voting and dispositive power over the securities held by the USVP Funds. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 2,245,605 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 1

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP X

Disclosed balance after: 5,239,744

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F2 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP") and USVP X Affiliates Fund , L.P. ("AFF X" and, together with USVP X, the "USVP Funds", and may be deemed to have sole voting and dispositive power over the securities held by the USVP Funds. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
November 17, 2020 Filed Jan 21, 2021 22:59 UTC Amendment Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 67,730 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-21-000006 · edgar.xml · nonDerivative · entry 1

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly held by Casey M.Tansey.

Disclosed balance after: 165,692

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F2 · balance_after: The original Form 4 filed on November 19, 2020, is being amended by this Form 4 amendment solely to correct an adminstrative error, which incorrectly underreported the amount of shares indirectly owned by the Reporting Person listed in column 5 as 67,730 shares instead of 165,692.shares.

F3 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMGX Distribution. Shares are held directly by the Reporting Person.

Read SEC document
October 09, 2020 Filed Oct 13, 2020 20:17 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 GrantCommon Stock 105 $130.00 $13,650.00
Disclosure

SEC source: 0001104659-20-114517 · a4.xml · nonDerivative · entry 1

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,935

F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy.

Read SEC document
September 14, 2020 Filed Sep 16, 2020 21:47 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 SaleCommon Stock 2,026 $130.01 $263,400.26
Disclosure

SEC source: 0001104659-20-105743 · a4.xml · nonDerivative · entry 3

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,830

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.98 to $130.05. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 14, 2020 Filed Sep 16, 2020 21:47 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 SaleCommon Stock 6,154 $129.45 $796,635.30
Disclosure

SEC source: 0001104659-20-105743 · a4.xml · nonDerivative · entry 2

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,856

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.97 to $129.94. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 14, 2020 Filed Sep 16, 2020 21:47 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 SaleCommon Stock 3,820 $128.58 $491,175.60
Disclosure

SEC source: 0001104659-20-105743 · a4.xml · nonDerivative · entry 1

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,010

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.97 to $128.96. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 10, 2020 Filed Jul 14, 2020 20:37 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 GrantCommon Stock 149 $0.00 $0.00
Disclosure

SEC source: 0001104659-20-083451 · a4.xml · nonDerivative · entry 1

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,830

F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy.

Read SEC document
June 15, 2020 Filed Jun 17, 2020 20:15 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 SaleCommon Stock 24,563 $85.28 $2,094,732.64
Disclosure

SEC source: 0001104659-20-074178 · a4.xml · nonDerivative · entry 6

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,681

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.10 to $85.66. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 15, 2020 Filed Jun 17, 2020 20:15 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 SaleCommon Stock 33,552 $84.75 $2,843,532.00
Disclosure

SEC source: 0001104659-20-074178 · a4.xml · nonDerivative · entry 5

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,244

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.11 to $85.09. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 15, 2020 Filed Jun 17, 2020 20:15 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 SaleCommon Stock 26,353 $83.53 $2,201,266.09
Disclosure

SEC source: 0001104659-20-074178 · a4.xml · nonDerivative · entry 4

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,796

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.10 to $84.09. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 15, 2020 Filed Jun 17, 2020 20:15 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 SaleCommon Stock 4,383 $82.70 $362,474.10
Disclosure

SEC source: 0001104659-20-074178 · a4.xml · nonDerivative · entry 3

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,149

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.11 to $83.09. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 15, 2020 Filed Jun 17, 2020 20:15 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 SaleCommon Stock 5,198 $81.85 $425,456.30
Disclosure

SEC source: 0001104659-20-074178 · a4.xml · nonDerivative · entry 2

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,532

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.10 to $82.09. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 15, 2020 Filed Jun 17, 2020 20:15 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 SaleCommon Stock 5,951 $80.12 $476,794.12
Disclosure

SEC source: 0001104659-20-074178 · a4.xml · nonDerivative · entry 1

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,730

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.85. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionSeries C Preferred Stock · Derivative 72,887 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 13

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by AFF X

Disclosed balance after: 0

Underlying: Common Stock · 72,887 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionSeries C Preferred Stock · Derivative 2,278,331 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 12

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP X

Disclosed balance after: 0

Underlying: Common Stock · 2,278,331 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionSeries B Preferred Stock · Derivative 92,771 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 11

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by AFF X

Disclosed balance after: 0

Underlying: Common Stock · 92,771 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionSeries B Preferred Stock · Derivative 2,899,876 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 10

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP X

Disclosed balance after: 0

Underlying: Common Stock · 2,899,876 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionSeries A Preferred Stock · Derivative 73,809 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 9

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by AFF X

Disclosed balance after: 0

Underlying: Common Stock · 73,809 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionSeries A Preferred Stock · Derivative 2,307,142 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 8

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP X

Disclosed balance after: 0

Underlying: Common Stock · 2,307,142 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 PurchaseCommon Stock 97,962 $19.00 $1,861,278.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · nonDerivative · entry 7

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Casey Tansey

Disclosed balance after: 97,962

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionCommon Stock 72,887 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · nonDerivative · entry 6

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by AFF X

Disclosed balance after: 239,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionCommon Stock 92,771 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · nonDerivative · entry 5

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by AFF X

Disclosed balance after: 166,580

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.